We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A financing round to develop a next-generation antibody therapy for ATTR amyloidosis.
This funding will enable Immutrin to advance its lead antibody candidate through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis. Unlike existing treatments, which focus on slowing or suppressing amyloid production, Immutrin’s approach is designed to actively remove pre-existing amyloid deposits from tissues – addressing a major unmet need in the field.
Amyloidosis is a group of rare diseases caused by misfolded proteins that accumulate in organs, leading to progressive and irreversible damage. Effective removal of these deposits is widely seen as critical to restoring organ function and improving long-term patient outcomes. Immutrin’s antibody selectively binds to amyloid fibrils and triggers a targeted immune response to clear these deposits. While initially focused on ATTR cardiomyopathy, the approach may have broader potential across other forms of amyloidosis.
Immutrin was established by Cambridge Innovation Capital and academic founders Professor Sir Mark Pepys, FRS; Nobel Laureate Sir Gregory Winter, FRS; and Professor Daniel Christ. Immutrin’s approach is based on decades of pioneering work by Professor Pepys elucidating ways to activate the body’s natural defence mechanisms to directly remove amyloid from tissues, combined with the world-leading antibody expertise of Sir Gregory and Professor Christ, pioneers of antibody display and humanisation.
As an incubator company within the Milner ecosystem, Immutrin exemplifies the Institute’s mission to translate cutting-edge science into impactful therapeutics. This significant investment marks an important milestone as the company moves toward clinical validation of a potentially transformative treatment for amyloidosis.
Many congratulations to the Immutrin team! We look forward to welcoming CEO Mihriban Tuna as a speaker at the Milner Therapeutics Symposium later this year.
Having been involved in building Immutrin from its earliest days, I’m delighted to welcome support from our new and existing investors in this strong global syndicate. The depth of investor confidence speaks to the strength of our approach, the clear differentiation of our lead asset, and the genuine opportunity to transform outcomes for patients with ATTR amyloidosis.
